Download PDF
Thromb Haemost 1964; 12(01): 087-104
DOI: 10.1055/s-0038-1655577
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Fibrinolysis and Fibrinogen Breakdown Products (Antithrombin VI) in Renal Venous Blood (RVB) in Dog[*]

K Worowski
1   Department of Physiological Chemistry, Medical School, Bialystok, Poland
,
S Niewiarowski
1   Department of Physiological Chemistry, Medical School, Bialystok, Poland
,
J Prokopowicz
1   Department of Physiological Chemistry, Medical School, Bialystok, Poland
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

The authors investigated fibrinolytic system of renal venous blood (RVB) peripheral venous blood (PVB) in normal dogs and in those with kidney injury produced by mercury chloride. An increase of fibrinolytic activity as well as a decrease of the level of plasminogen and fibrinogen were found in RVB plasma of normal dogs. An inhibition of the fibrinolytic activity was found in intoxicated dogs in both RVB and PVB plasmas, followed by an increase of plasminogen and fibrinogen levels. The occurence of fibrinogen breakdown products, antithrombin VI, was demonstrated in RVB plasma of normal dogs. It does not appear in RVB plasma of intoxicated dogs.

On the basis of experimental results an important role of urokinase, secreted by the kidney into the general circulation is suggested as regards the maintenance of the coagulation and fibrinolysis balance in the organism as well as in the fibrinogen and plasminogen catabolism.

It has been also concluded that the antithrombin VI, formed in the kidney circulation is a natural inhibitor of blood coagulation appearing in physiological conditions.

* Aided in part by the grant from Biochemical and Biophysical Committee, Department II, Polish Academy of Sciences.


 

  • References

  • 1 Alexander B, Pechet L, Kliman A. Proteolysis, fibrinolysis and coagulation. Circulation 20: 596 1962;
    PubMedGoogle Scholar
  • 2 Astrup T, Müllertz S. The fibrin plate method for estimation fibrinolytic activity. Arch. Biochem. 40: 346 1952;
    CrossrefPubMedGoogle Scholar
  • 3 Astrup T, Sterndorff I. An activator of plasminogen in normal urine. Proc. Soc. exp. Biol. (N. Y.) 57: 675 1952;
    PubMedGoogle Scholar
  • 4 Astrup T, Sterndorff I. Fibrinolysokinase activity in animal and human tissue. Acta physiol. scand. 37: 41 1956;
    PubMedGoogle Scholar
  • 5 Bar-Pratkowska J, Niewiarowska M, Roszkowski I. Fibrinogen derived coagulation inhibitors in obstetrical fibrinolysis. Thrombos. Diathes. haemorrh. (Stuttg.) (submitted)
    PubMedGoogle Scholar
  • 6 Bjerrehuus J. The fibrinolytic activity of urine. Scand. J. clin. Lab. Invest. 4: 179 1952;
    CrossrefPubMedGoogle Scholar
  • 7 Budzynski A. Z, Batallo Z, Lipiúski B, Kowalski E. The effect of pH on the interaction of fibrinogen degradation products (FDP) with the fibrinogen-fibrin conversion. Bull. Acad, poi. Sci. 11: 477 1963;
    PubMedGoogle Scholar
  • 8 Buluk K, Bielawiec M. Badania nad zawartoscia urokinazy w moczu róznych zwierzat i czlowieka. Pol. Arch. Med. Wewnet. 32: 773 1962;
    PubMedGoogle Scholar
  • 9 Buluk K, Furman M. On the controlling function of the kidneys in fibrinolysis. Experientia (Basel) 18: 146 1962;
    CrossrefPubMedGoogle Scholar
  • 10 Buluk K, Malofiejew M. Otrzymywanie aktywatora fibrynolizy w nerce poza ustrojem (aktywator fibrynolizy w izolowanej nerce). Acta Physiol, pol. 14: 371 1963;
    PubMedGoogle Scholar
  • 11 Deutsch E, Fischer M. Die Wirkung intravenös applizierter Streptokinase auf Fibrinolyse und Blutgerinnung. Thrombos. Diathes. haemorrh. (Stuttg.) 4: 482 1960;
    PubMedGoogle Scholar
  • 12 Egeberg O. Blood coagulation in renal failure. Scand. J. clin. Lab. Invest. 14: 163 1962;
    CrossrefPubMedGoogle Scholar
  • 13 Fletcher A, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J. clin. Invest. 38: 1096 1959;
    CrossrefPubMedGoogle Scholar
  • 14 Fletcher A. P, Alkjaersig N, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. clin. Invest. 4: 896 1961;
    PubMedGoogle Scholar
  • 15 Gross R, Nieth H, Mammen E. Blutungsbereitschaft und Gerinnungsstörungen bei Urämie. Klin. Wschr. 36: 107 1958;
    CrossrefPubMedGoogle Scholar
  • 16 Guest M. M, Geländer D. R. Urokinase: Physiologie activator of Profibrinolysin. Texas Rep. Biol. Med. 19: 89 1961;
    PubMedGoogle Scholar
  • 17 Janczarski I, Kaleta Z, Lesniewski W. Wplyw nerek i sledziony na przemiane bialkowa ustroju. I Krajowy Kongres Biochemii Lodz, 1963, p. 65
    PubMedGoogle Scholar
  • 18 v. Kaulla K.N, Riggenbach N. Urokinase excretion in man. Thrombos. Diathes. haemorrh. (Stuttg.) 5: 162 1961;
    PubMedGoogle Scholar
  • 19 v. Kaulla K. N, Swan H, Kaulla E. Beobachtungen von Gerinnung und Fibrinogen während chirurgischer Eingriffe am menschlichen Herzen in Unterkühlung oder mittels extrakorporalen Kreislaufes. Klin. Wschr. 36: 1050 1958;
    CrossrefPubMedGoogle Scholar
  • 20 Kendall A. G, Lowenstein L, Morgen B. O. The haemorrhagic diathesis in renal disease. Cañad, med. Ass. J. 85: 405 1961;
    PubMedGoogle Scholar
  • 21 Kekwick B. A, Mackay M. E, Nance M. H, Record B. B. The purification of human fibrinogen. Biochem. J. 60: 671 1955;
    PubMedGoogle Scholar
  • 22 Kjeldgaard N. O, Ploug J. Urokinase an activator of plasminogen from human urine. II. Mechanism of plasminogen activation. Biochim. biophys. (Amst.) 24: 283 1957;
    PubMedGoogle Scholar
  • 23 Kline D. L. The purification and cristallisation of plasminogen (Profibrinolysin). J.biol. Chem. 204: 949 1953;
    PubMedGoogle Scholar
  • 24 Kopec M. Fibrynoliza utajona i jej znaczenie w fizjopatologi i klinice. P. W. N. Warszawa 1963
    PubMedGoogle Scholar
  • 25 Kowalski E. Fibrinogen derived inhibitors of blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. No. 1: 211 1960;
    PubMedGoogle Scholar
  • 26 Kowalski E, Budzynski A, Kopec M, Batallo Z, Lipinski B, Wegrzynowicz Z. Studies on the molecular pathology of bleeding in severe fibrinolytic states in dogs. Thrombos. Diathes. haemorrh. (Stuttg.) 12: 69 1964;
    PubMedGoogle Scholar
  • 27 Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for the determination of fibrinolysis. J. clin. Path. 12: 215 1959;
    CrossrefPubMedGoogle Scholar
  • 28 Kowalski E, Batallo Z, Niewiarowski S, Marczak K, Panasewicz J. Wplyw plazminy i streptokinazy na uklad krzepniecia krwi kota in vivo. Pol. Tyg. lek 12: 1221 1957;
    PubMedGoogle Scholar
  • 29 Batallo Z. Critical evaluation of the thrombin time test. Proc. of the eighth Congress of the Europ. Soc. Haem. Wien, 423 (1961). Karger Basel – New York, 1962
    PubMedGoogle Scholar
  • 30 Lewis J. H, Ferguson J. H. Partial purification of human prothrombin and proconvertin, their characteristisc and interaction. J. clin. Invest. 32: 915 1953;
    CrossrefPubMedGoogle Scholar
  • 31 Lewis J. H, Zucker M. B, Ferguson J. H. Bleeding tendency in uremia. Blood 11: 1073 1965;
    PubMedGoogle Scholar
  • 32 Niewiarowski S. L’ adsorption des facteurs du système fìbrinolytique par la bentonite. Pathet. Biol. 7: 2557 1959;
    PubMedGoogle Scholar
  • 33 Niewiarowski S, Kopec M. Etudes sur la rôle de la fibrinolyse dans la pathogénie des diatheses hémorragiques. Hémostase 1: 237 1961;
    PubMedGoogle Scholar
  • 34 Niewiarowski S, Kowalski E. Un nouvel anticoagulant derivé du fibrinogène. Rev. hémat. 15: 320 1958;
    PubMedGoogle Scholar
  • 35 Niewiarowski S, Prokopowicz J, Poplawski A, Worowski K. Inhibition of dog fibrinolytic system in experimental tubular necrosis of kidney. Experientia (Basel) 2: 99 1964;
    PubMedGoogle Scholar
  • 36 Niewiarowska M, Wegrzynowicz Z. Influence of dieoumarol derivatives on plasma fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg.) 3: 279 1959;
    PubMedGoogle Scholar
  • 37 Nilsson I. M, Olow B. Determination of fibrinogen and fibrinogenolytic activity. Thrombos. Diathes. haemorrh. (Stuttg.) 8: 297 1962;
    PubMedGoogle Scholar
  • 38 Painter R. H, Charles A. F. Characterization of a soluble plasminogen activator from kidney cell cultures. Amer. J. Physiol. 202: 1125 1962;
    PubMedGoogle Scholar
  • 39 Ploug J, Kjeldgaard N. O. Urokinase an activator of plasminogen from human urine. I. Isolation and properties. Biochim. biophys. Acta (Amst.) 24: 278 1957;
    CrossrefPubMedGoogle Scholar
  • 40 Prokopowicz J, Rejniak L, Niewiarowski S, Worowski K. Fibrinolytic activity of tissue slices of dog kidney. (In preparation.)
    PubMedGoogle Scholar
  • 41 Quick A. J. The physiology and pathology of haemostasis. Kimpton; London: 1951
    Google Scholar
  • 42 Schultz F. H. Das Fibrinogen. VEB Georg Thieme; Leipzig: 1953
    Google Scholar
  • 43 Sobel G. W, Möhler S. R, Jones N. W, Dowdy A. B. C, Guest M. M. Urokinase: an activator of plasma Profibrinolysin, extracted from urine. Amer. J. Physiol. 171: 768 1952;
    PubMedGoogle Scholar
  • 44 Williams J. R. B. The fibrinolytic activity of urine. Brit. J. exp. Path. 32: 530 1951;
    PubMedGoogle Scholar
  • 45 Worowski K, Prokopowicz J, Niewiarowski S. Unpublished results.
    PubMed
  • 46 Zaman C. L. Fibrinolysis in pleural cavity after pulmonary resection. II. Antithrombin activity of the pleural exsudate after pulmonary resection (significance of fibrinolysis for haemostasis). Thrombos. Diathes. haemorrh. (Stuttg.) 9: 211 1963;
    PubMedGoogle Scholar
  • 47 Zywicka H, Kopec M, Batallo Z, Kowalski E. Anticoagulant circulant ressemblant à l’antithrombine VI au cours d’un lupus erythémateux disséminé. Thrombos. Diathes. haemorrh. (Stuttg.) 6: 63 1961;
    PubMedGoogle Scholar